Healthcare and Pharmaceutical Sector

The FDA published a discussion paper Tuesday seeking public input on how to regulate generative AI medical devices, proposing a "competency-based" premarket evaluation modeled on physician licensing exams. The agency's Center for Devices and Radiological Health would test the final user-facing AI product—not underlying models—to verify it demonstrates clinical knowledge, safety behavior, and generalizability for its intended use, with rigor scaled to the device's risk profile. Testing alone may not suffice; the FDA is also considering real-world evidence collection through standardized patient interactions, prospective clinical studies, or shadow deployment to confirm performance in actual clinical settings. The framework acknowledges that generative AI poses distinct risks compared to traditional software: devices can accept open-ended inputs, produce variable outputs, hallucinate plausibly false information, and evolve over time in ways that degrade performance unpredictably. The FDA has authorized over 1,000 AI-enabled devices to date, but most do not incorporate generative AI. The agency is accepting public comments through October 19 and has framed the discussion paper around targeted questions rather than binding guidance, signaling it is still determining whether competency-based testing, risk-proportionate postmarket monitoring, or other approaches best balance innovation speed with patient safety. The effort aligns with the Trump Administration's stated priority to accelerate AI medical product delivery to market.

Employers are planning to cut healthcare benefits next year to limit cost increases to 9.7% rather than face an otherwise expected 11.1% jump, according to a preview of WTW's 2026 Best Practices In Healthcare Survey reviewed by CFO Dive. The cost pressure is real: Aon reported separately that average employer plan costs rose 8.8% to $14,432 per employee in 2026, while worker premiums jumped 6.4% to $3,130. Companies are restricting eligibility, raising out-of-pocket expenses, and pushing more costs onto workers' paychecks. The drivers are chronic disease prevalence, GLP-1 drug spending, and higher coding and documentation costs tied to AI adoption. Yet nearly half of surveyed employers see "significant" changes coming in the next three years, and 56% say they are unwilling to take "disruptive" actions—a signal that the math is forcing their hand even as they resist it. The risk is tangible: Starbucks ended GLP-1 coverage in August, prompting the Obesity Action Coalition to call the move a betrayal of the company's benefits reputation and demand reversal. Employers cutting benefits face a trade-off between controlling costs and retaining talent.

A 6-year-old girl died following an experimental gene-editing treatment in China, and the research team failed to disclose either her death or her family's $860,000 financial contribution to the work in a subsequent Nature publication. The girl's parents paid the substantial sum to fund preclinical development of a therapy for a rare genetic defect causing developmental delays, developed by neuroscientist Qiu Zilong at a prestigious Chinese university. After the treatment, she developed complications and died; the hospital's ethics board concluded the death was related to the therapy, yet imposed minimal penalties and kept the outcome from the public. The Nature paper, which described only preclinical feasibility work, made no mention of the human trial or the girl's death—a gap that Nature's deputy editor Victoria Aranda said occurred because no information about a planned trial in people was ever shared with the journal during peer review. The omission is significant because it potentially misled readers about the risks and limitations of the underlying science. The case exposes China's dual-track regulatory system, which permits investigator-initiated trials with less oversight than conventional pathways, and raises questions about whether financial entanglement between families and researchers can compromise judgment about trial safety. Investigations by Nature and Shanghai Jiao Tong University School of Medicine are underway. The incident arrives as China's clinical trial starts now nearly match the US in volume, making the gap between regulatory ambition and ethical enforcement newly visible.